Current pharmacotherapy for tic disorders

References

• Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25(11):1538–1549. PubMed Central PMCID: PMCPMC2929378.
   PubMed Web of Science ®Google Scholar
• Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100–112.
   PubMed Web of Science ®Google Scholar
• Scharf JM, Miller LL, Gauvin CA, et al. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30(2):221–228.
   PubMed Web of Science ®Google Scholar
• Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77–90.
   PubMed Web of Science ®Google Scholar
• Morand-Beaulieu S, Grot S, Lavoie J, et al. The puzzling question of inhibitory control in Tourette syndrome: A meta-analysis. Neurosci Biobehav Rev. 2017;80:240–262.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012;57(3):133–143.
   PubMed Web of Science ®Google Scholar
• Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother. 2018;18(2):125–137.
   PubMed Web of Science ®Google Scholar
• Ganos C, Martino D, Pringsheim T. Tics in the pediatric population: pragmatic management. Mov Disord Clin Pract. 2017;4(2):160–172. PubMed Central PMCID: PMCPMC5396140. .
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907–915.
   PubMed Web of Science ®Google Scholar
• Pandey S, Dash D. Progress in pharmacological and surgical management of tourette syndrome and other chronic tic disorders. Neurologist. 2019;24(3):93–108.
   PubMed Web of Science ®Google Scholar
• Artukoglu BB, Bloch MH. The potential of cannabinoid-based treatments in tourette syndrome. CNS Drugs. 2019;33(5):417–430. Epub 2019/04/13. PubMed PMID: 30977108.
   PubMed Web of Science ®Google Scholar
• Kumar A, Duda L, Mainali G, et al.A comprehensive review of tourette syndrome and complementary alternative medicine.Curr Dev Disord Rep.2018;5(2):95–100. Epub 2018/05/15. PubMed PMID: 29755921. PubMed Central PMCID: PMCPMC5932093.
   PubMedGoogle Scholar
• Frundt O, Woods D, Ganos C.Behavioral therapy for tourette syndrome and chronic tic disorders.Neurol Clin Pract.2017;7(2):148–156. Epub 2017/12/01. PubMed PMID: 29185535. PubMed Central PMCID: PMCPMC5669407.
   PubMedGoogle Scholar
• Roessner V, Plessen KJ, Rothenberger A, et al.European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173–196. DOI:10.1007/s00787-011-0163-7 PubMed Central PMCID: PMCPMC3065650.
   PubMed Web of Science ®Google Scholar
• Giovannitti JA Jr., Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31–39. PubMed Central PMCID: PMCPMC4389556.
   PubMedGoogle Scholar
• Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. Faseb J. 1992;6(3):832–839.
   PubMed Web of Science ®Google Scholar
• Arnsten AFT, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211–216.
   PubMed Web of Science ®Google Scholar
• Huss M, Chen W, Ludolph AG. guanfacine extended release: a new pharmacological treatment option in Europe. Clin Drug Investig. 2016;36(1):1–25. PubMed Central PMCID: PMCPMC4706844.
   PubMed Web of Science ®Google Scholar
• Hamamoto Y, Fujio M, Nonaka M, et al. Expert consensus on pharmacotherapy for tic disorders in Japan. Brain Dev. 2019;41(6):501–506.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–13. PubMed Central PMCID: PMCPMC3387872.
   PubMed Web of Science ®Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–179.
   PubMed Web of Science ®Google Scholar
• Joo SW, Kim H-W. Treatment of children and adolescents with attention deficit hyperactivity disorder and/or tourette’s disorder with clonidine extended release. Psychiatry Investig. 2018;15(1):90–93.
   PubMed Web of Science ®Google Scholar
• Leckman JF. Clonidine Treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1991;48(4):324.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Wilson RS, et al. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol. 1987;21(3):307–310.
   PubMed Web of Science ®Google Scholar
• Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol. 2009;40(6):420–425.
   PubMed Web of Science ®Google Scholar
• Tourette’s Syndrome Study G. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527–536. Epub 2002/ 02/28. doi: . PubMed PMID: 11865128.
   PubMed Web of Science ®Google Scholar
• Singer HS, Brown J, Quaskey S, et al. the treatment of attention-deficit hyperactivity disorder in tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995;95(1):74–81.
   PubMed Web of Science ®Google Scholar
• Song -P-P, Jiang L, Li X-J, et al. The efficacy and tolerability of the clonidine transdermal patch in the treatment for children with tic disorders: a prospective, open, single-group, self-controlled study. Front Neurol. 2017;8. DOI:10.3389/fneur.2017.00032
   PubMed Web of Science ®Google Scholar
• Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1986;31(4):301–336.
   PubMed Web of Science ®Google Scholar
• Scahill L, Leckman JF, Schultz RT, et al.A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130–1135. DOI:10.1212/01.wnl.0000055434.39968.67.
   PubMed Web of Science ®Google Scholar
• Ming X, Mulvey M, Mohanty S, et al. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther. 2011;2:105–112. PubMed Central PMCID: PMCPMC3926778.
   PubMedGoogle Scholar
• Murphy TK, Fernandez TV, Coffey BJ, et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol. 2017;27(9):762–770.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896–906.
   PubMed Web of Science ®Google Scholar
• Ganos C, Roessner V, Münchau A. The functional anatomy of Gilles de la Tourette syndrome. Neurosci Biobehav Rev. 2013;37(6):1050–1062.
   PubMed Web of Science ®Google Scholar
• Maia TV, Conceição VA. Dopaminergic disturbances in tourette syndrome: an integrative account. Biol Psychiatry. 2018;84(5):332–344.
   PubMed Web of Science ®Google Scholar
• Chapel JL, Brown N, Jenkins RLTourette's disease: symptomatic relief with haloperidol. Am J Psychiatry. 1964;121;608–10. DOI:10.1176/ajp.121.6.608.
   PubMed Web of Science ®Google Scholar
• Müller-Vahl KR, Berding G, Kolbe H, et al. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol Scand. 2000;101(3):165–171.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Ho J, Sarna JR, et al. Feasibility and relevance of antipsychotic safety monitoring in children with tourette syndrome: a prospective longitudinal study. J Clin Psychopharmacol. 2017;37(5):498–504.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Panagiotopoulos C, Davidson J, et al. Canadian Alliance for Monitoring E, Safety of antipsychotics in children guideline g. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health. 2011;16(9): 581–589. PubMed Central PMCID: PMCPMC3223902.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. Am J Psychiatry. 1997;154(8):1057–1062. Epub 1997/08/01. doi: . PubMed PMID: 9247389.
   PubMed Web of Science ®Google Scholar
• Shapiro E. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46(8):722.
   PubMed Web of Science ®Google Scholar
• Singer HS, Gammon K, Quaskey S. Haloperidol fluphenazine and clonidine in tourette syndrome: controversies in treatment. Pediatr Neurosurg. 1985;12(2):71–74.
   Google Scholar
• Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette’s syndrome. Am J Psychiatry. 1978;135(5):585–587.
   PubMed Web of Science ®Google Scholar
• Budman CL. The role of atypical antipsychotics for treatment of tourette’s syndrome: an overview. Drugs. 2014;74(11):1177–1193.
   PubMed Web of Science ®Google Scholar
• Colvin CL, Tankanow RM. Pimozide: use in Tourette’s syndrome. Drug Intell Clin Pharm. 1985;19(6):421–424.
   PubMedGoogle Scholar
• Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of tourette syndrome. CNS Drugs. 2018;32(1):33–45. PubMed Central PMCID: PMCPMC5843687.
   PubMed Web of Science ®Google Scholar
• Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in tourette’s disorder. J Clin Psychiatry. 2001;62(1):50–56.
   PubMed Web of Science ®Google Scholar
• Gilbert DL, Robert Batterson J, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43(2):206–214.
   PubMed Web of Science ®Google Scholar
• Borison RL, Ang L, Hamilton WJ, et al. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull. 1983;11(2):205–208. Epub 1983/08/01. PubMed PMID: 6578865.
   PubMed Web of Science ®Google Scholar
• Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126–130. Epub 2013/ 10/24. doi: . PubMed PMID: 24150997.
   PubMed Web of Science ®Google Scholar
• Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with tourette’s syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41(3):330–336.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292–299.
   PubMed Web of Science ®Google Scholar
• Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22(1):31–39.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Joung YS, Lee J-S, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with tourette’s disorder. J Clin Psychiatry. 2013;74(08):e772–e80.
   PubMedGoogle Scholar
• Rickards H, Cavanna AE, Worrall R. Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol. 2012;16(4):361–364.
   PubMed Web of Science ®Google Scholar
• Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. Neurol Neurochir Pol. 2018;52(1):84–87.
   PubMed Web of Science ®Google Scholar
• Gerasch S, Kanaan AS, Jakubovski E, et al. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front Neurosci. 2016;10:416. PubMed Central PMCID: PMCPMC5018494.
   PubMed Web of Science ®Google Scholar
• Zheng W, Li X-B, Xiang Y-Q, et al. Aripiprazole for Tourette’s syndrome: a systematic review and meta-analysis. Hum Psychopharmacol. 2016;31(1):11–18.
   PubMed Web of Science ®Google Scholar
• Sallee F, Kohegyi E, Zhao J, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(9):771–781.
   PubMed Web of Science ®Google Scholar
• Liu -Y-Y, Chen Y-H, Chen H, et al. A control study of aripiprazole and tiapride treatment for tic disorders in children. Zhongguo Dang Dai Er Ke Za Zhi. 2010;12(6):421–424.
   PubMedGoogle Scholar
• Zheng Y, Zhang Z-J, Han X-M, et al. A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. J Child Psychol Psychiatry. 2016;57(1):74–83.
   PubMed Web of Science ®Google Scholar
• Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988;237(4):223–229.
   PubMedGoogle Scholar
• Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol. 1990;13(3):229–235. Epub 1990/06/01. PubMed PMID: 2357704.
   PubMed Web of Science ®Google Scholar
• Ho C-S, Chen H-J, Chiu N-C, et al. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc. 2009;108(10):788–793. Epub 2009/10/30. doi: . PubMed PMID: 19864199.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70–73.
   PubMed Web of Science ®Google Scholar
• Donegan S, Dixon P, Hemming K, et al. A systematic review of placebo-controlled trials of topiramate: how useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug? Epilepsia. 2015;56(12):1910–1920.
   PubMed Web of Science ®Google Scholar
• Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77(6):958–964.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitão CB, Pinto LC, et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(5):e338–47.
   PubMed Web of Science ®Google Scholar
• Azar NJ, Wright AT, Wang L, et al. Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal. Neurology. 2008;70(22,Part 2):2187–2188.
   PubMed Web of Science ®Google Scholar
• Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274–279.
   PubMed Web of Science ®Google Scholar
• Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005;63(1):180–185.
   PubMed Web of Science ®Google Scholar
• Marras C, Andrews D, Sime E, et al. Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial. Neurology. 2001;56(5):605–610.
   PubMed Web of Science ®Google Scholar
• Castelão M, Marques RE, Duarte GS, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2017;12:CD003633. PubMed Central PMCID: PMCPMC6486222.
   PubMed Web of Science ®Google Scholar
• Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;(5):CD004315. DOI:10.1002/14651858.CD004315.pub3.
   PubMed Web of Science ®Google Scholar
• Bilyk JR, Yen MT, Bradley EA, et al. Chemodenervation for the treatment of facial dystonia: a report by the American academy of ophthalmology. Ophthalmology. 2018;125(9):1459–1467.
   PubMed Web of Science ®Google Scholar
• Parsons SM. Transport mechanisms in acetylcholine and monoamine storage. Faseb J. 2000;14(15):2423–2434.
   PubMed Web of Science ®Google Scholar
• Schütz B, Schäfer MK, Eiden LE, et al. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut. Brain Res Dev Brain Res. 1998;106(1–2):181–204.
   PubMedGoogle Scholar
• Lees AJ, Tolosa E, Warren Olanow C. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord. 2015;30(1):19–36.
   PubMed Web of Science ®Google Scholar
• Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251(25):1006–1008.
   PubMed Web of Science ®Google Scholar
• Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2015;30(1):4–18.
   PubMed Web of Science ®Google Scholar
• Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983;225(3):515–521.
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol. 1984;102(3–4):425–430.
   PubMed Web of Science ®Google Scholar
• Group HS, Huntington Study G. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. 2006;66(3): 366–372.
   PubMed Web of Science ®Google Scholar
• Frank S. Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.. BMC Neurol. 2009;9(1). DOI:10.1186/1471-2377-9-62
   PubMedGoogle Scholar
• Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38(3):391–394.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette’s syndrome. Neurology. 1984;34(5):688.
   PubMed Web of Science ®Google Scholar
• Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4(1). DOI:10.1186/s40734-017-0051-5
   PubMedGoogle Scholar
• Rodrigues FB, Duarte GS, Costa J, et al. Tetrabenazine versus deutetrabenazine for Huntington’s disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4(4):582–585.
   PubMed Web of Science ®Google Scholar
• DeWitt SH, Maryanoff BE. Deuterated drug molecules: focus on FDA-approved deutetrabenazine. Biochemistry. 2018;57(5):472–473.
   PubMed Web of Science ®Google Scholar
• Frank S, Testa CM, Stamler D, Huntington Study G. et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40–50.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with tourette syndrome. Tremor Other Hyperkinet Mov. 2016;6:422. PubMed Central PMCID: PMCPMC5133390.
   PubMed Web of Science ®Google Scholar
• Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol. 2019;42(2):37–41.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017;174(5):476–484.
   PubMed Web of Science ®Google Scholar
• Kim ES. Valbenazine: first global approval. Drugs. 2017;77(10):1123–1129.
   PubMed Web of Science ®Google Scholar
• Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015;24(6):737–742.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–2470.
   PubMed Web of Science ®Google Scholar
• Neurocrine Biosciences Inc. Neurocrine Biosciences announces topline data from phase IIb T-Force GOLD study demonstrating valbenazine did not meet primary endpoint in pediatric patients with Tourette Syndrome. 2018. [cited 2020 Jan 8].
   Google Scholar
• clinicaltrials.gov. deutetrabenazine tics. [cited 2020 Jan 9]. Available from: https://clinicaltrials.gov/ct2/results?cond=tics&term=deutetrabenazine&cntry=&state=&city=&dist=.
   Google Scholar
• Qi Y, Zheng Y, Li Z, et al. Genetic studies of tic disorders and tourette syndrome. Methods Mol Biol. 2019;547–571. DOI:10.1007/978-1-4939-9554-7_32
   PubMedGoogle Scholar
• Andrén P, Aspvall K, de la Cruz LF, et al. Therapist-guided and parent-guided internet-delivered behaviour therapy for paediatric Tourette’s disorder: a pilot randomised controlled trial with long-term follow-up. BMJ Open. 2019;9(2):e024685. PubMed Central PMCID: PMCPMC6398666.
   PubMedGoogle Scholar
• Jakubovski E, Reichert C, Karch A, et al. The ONLINE-TICS study protocol: a randomized observer-blind clinical trial to demonstrate the efficacy and safety of internet-delivered behavioral treatment for adults with chronic tic disorders. Front Psychiatry. 2016;7. DOI:10.3389/fpsyt.2016.00119
   PubMed Web of Science ®Google Scholar
• Nosratmirshekarlou E, Shafiq S, Goodarzi ZS, et al. Effect of diet, exercise and sleep on tic severity: a scoping review protocol. BMJ Open. 2019;9(7):e024653.
   PubMed Web of Science ®Google Scholar
• Heise KF, Steven B, Liuzzi G, et al. Altered modulation of intracortical excitability during movement preparation in Gilles de la Tourette syndrome. Brain. 2010;133(2):580–590.
   PubMedGoogle Scholar
• Müller-Vahl KR, Sambrani T, Jakubovski E. Tic disorders revisited: introduction of the term “tic spectrum disorders”. Eur Child Adolesc Psychiatry. 2019;28:1129–1135.
   Web of Science ®Google Scholar
• Müller-Vahl K, Dodel I, Müller N, et al. Health-related quality of life in patients with Gilles de la Tourette’s syndrome. Mov Disord. 2010;25(3):309–314.
   PubMed Web of Science ®Google Scholar
• Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016;315(18):1997–2008.
   PubMed Web of Science ®Google Scholar
• Wolraich M, Brown L, Brown RT, Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022. PubMed Central PMCID: PMCPMC4500647.
   PubMed Web of Science ®Google Scholar
• Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54(9):728–736.
   PubMed Web of Science ®Google Scholar
• Freeman RD, Tourette Syndrome International Database C. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007;16(S1):15–23.
   PubMedGoogle Scholar
• Müller-Vahl KR, Roessner V, on behalf of the European Society for the Study of Tourette S. Treatment of tics in patients with Tourette syndrome: recommendations according to the European society for the study of tourette syndrome. Mov Disord. 2011;26(13):2447.
   PubMed Web of Science ®Google Scholar
• Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
   PubMed Web of Science ®Google Scholar
• Ho J, Panagiotopoulos C, McCrindle B, Canadian Alliance for Monitoring E, et al. Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth.Paediatr Child Health.2011;169:575–580. Epub 2012/ 11/02. PubMed PMID: 23115501. PubMed Central PMCID: PMCPMC3223901.
   PubMed Web of Science ®Google Scholar
• Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36(6):835–843.
   PubMed Web of Science ®Google Scholar
• Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1998;37(2):221–227.
   PubMed Web of Science ®Google Scholar
• Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clinical Neuropharmacology. 2002;25(6):325–332.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry and Human Development. 2014;45(5):596–603.
   PubMed Web of Science ®Google Scholar